Cargando…

Sequencing as a first-line methodology for cystic fibrosis carrier screening

PURPOSE: Medical society guidelines recommend offering genotyping-based cystic fibrosis (CF) carrier screening to pregnant women or women considering pregnancy. We assessed the performance of sequencing-based CF screening relative to genotyping, in terms of analytical validity, clinical validity, cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beauchamp, Kyle A., Johansen Taber, Katherine A., Grauman, Peter V., Spurka, Lindsay, Lim-Harashima, Jeraldine, Svenson, Ashley, Goldberg, James D., Muzzey, Dale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831513/ https://www.ncbi.nlm.nih.gov/pubmed/31036917 http://dx.doi.org/10.1038/s41436-019-0525-y

Ejemplares similares

Correction: Sequencing as a first-line methodology for cystic fibrosis carrier screening
por: Beauchamp, Kyle A., et al.
Publicado: (2019)

Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen
por: Beauchamp, Kyle A., et al.
Publicado: (2019)

Fragile X syndrome carrier screening accompanied by genetic consultation has clinical utility in populations beyond those recommended by guidelines
por: Johansen Taber, Katherine, et al.
Publicado: (2019)

Clinical utility of expanded carrier screening: results-guided actionability and outcomes
por: Johansen Taber, Katherine A., et al.
Publicado: (2018)

A data-driven evaluation of the size and content of expanded carrier screening panels
por: Ben-Shachar, Rotem, et al.
Publicado: (2019)

Clinical validity of expanded carrier screening: Evaluating the gene‐disease relationship in more than 200 conditions
por: Balzotti, Marie, et al.
Publicado: (2020)

Detecting clinically actionable variants in the 3′ exons of PMS2 via a reflex workflow based on equivalent hybrid capture of the gene and its pseudogene
por: Gould, Genevieve M, et al.
Publicado: (2018)

Systematic design and comparison of expanded carrier screening panels
por: Beauchamp, Kyle A, et al.
Publicado: (2018)

Technology-Driven Noninvasive Prenatal Screening Results Disclosure and Management
por: Arjunan, Aishwarya, et al.
Publicado: (2020)

Genetic ancestry analysis on >93,000 individuals undergoing expanded carrier screening reveals limitations of ethnicity-based medical guidelines
por: Kaseniit, Kristjan E., et al.
Publicado: (2020)

Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions
por: Miller, Aaron C., et al.
Publicado: (2020)

Evaluating the efficacy of three carrier screening workflows designed to identify at‐risk carrier couples
por: Arjunan, Aishwarya, et al.
Publicado: (2021)

Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs
por: Li, Hongyu, et al.
Publicado: (2019)

The impact of HBB‐related hemoglobinopathies carrier status on fetal fraction in noninvasive prenatal screening
por: Putra, Manesha, et al.
Publicado: (2022)

Noninvasive prenatal screening for patients with high body mass index: Evaluating the impact of a customized whole genome sequencing workflow on sensitivity and residual risk
por: Muzzey, Dale, et al.
Publicado: (2019)

Cystic fibrosis patients on cystic fibrosis transmembrane conductance regulator modulators have a reduced incidence of cirrhosis
por: Ramsey, Mitchell L, et al.
Publicado: (2022)

Deciding on cystic fibrosis carrier screening: three citizens’ juries and an online survey
por: Mosconi, Paola, et al.
Publicado: (2018)

Carrier Testing for Cystic Fibrosis: Knowledge and Attitudes within a Local Community
por: Magnay, D., et al.
Publicado: (1992)

Correction: Inaccuracies and shortcomings in “Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations”
por: Taber, Katherine Johansen, et al.
Publicado: (2019)

Inaccuracies and shortcomings in “Adherence of cell-free DNA noninvasive prenatal screens to ACMG recommendations”
por: Johansen Taber, Katherine, et al.
Publicado: (2019)

Management Issues for Adolescents with Cystic Fibrosis
por: Withers, Adelaide Lindsay
Publicado: (2012)

Preferences for Prenatal Tests for Cystic Fibrosis: A Discrete Choice Experiment to Compare the Views of Adult Patients, Carriers of Cystic Fibrosis and Health Professionals
por: Hill, Melissa, et al.
Publicado: (2014)

Obesity in cystic fibrosis
por: Kutney, Katherine A., et al.
Publicado: (2021)

Inter‐lab concordance of variant classifications establishes clinical validity of expanded carrier screening
por: Kaseniit, Kristjan E., et al.
Publicado: (2019)

Achromobacter spp. genetic adaptation in cystic fibrosis
por: Gabrielaite, Migle, et al.
Publicado: (2021)

Response to “Noninvasive prenatal screening at low fetal fraction: comparing whole‐genome sequencing and single‐nucleotide polymorphism methods”
por: Muzzey, Dale, et al.
Publicado: (2017)

Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel
por: Watson, Michael S., et al.
Publicado: (2004)

Cystic fibrosis: to screen or not to screen? Involving a Citizens' jury in decisions on screening carrier
por: Mosconi, Paola, et al.
Publicado: (2014)

Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers
por: Garbuzenko, O.B., et al.
Publicado: (2019)

Are cystic fibrosis mutation carriers a potentially highly vulnerable group to COVID‐19?
por: Sarantis, Panagiotis, et al.
Publicado: (2020)

COVID-19: Pathophysiology and implications for cystic fibrosis, diabetes and cystic fibrosis-related diabetes
por: Mason, Kelly, et al.
Publicado: (2021)

Cystic Fibrosis, CFTR, and Colorectal Cancer
por: Scott, Patricia, et al.
Publicado: (2020)

Pseudomonas Biofilms, Cystic Fibrosis, and Phage: a Silver Lining?
por: Brüssow, Harald
Publicado: (2012)

Transmission and Antibiotic Resistance of Achromobacter in Cystic Fibrosis
por: Gabrielaite, Migle, et al.
Publicado: (2021)

Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study
por: Dahl, Morten, et al.
Publicado: (2005)

A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis
por: Bombard, Yvonne, et al.
Publicado: (2016)

COVID-19 in a pregnant cystic fibrosis carrier with myasthenia gravis: A case report
por: Coté, John J., et al.
Publicado: (2022)

Cystic Fibrosis
por: Gibson, Lewis E.
Publicado: (1969)

Cystic Fibrosis
por: Dodge, J A
Publicado: (1997)

Parents' responses to receiving sickle cell or cystic fibrosis carrier results for their child following newborn screening
por: Ulph, Fiona, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lkq8eag8mvksr1cajhvomt19lu